心臟衰竭治療醫療設備市場規模、佔有率和成長分析：按器材類型、應用、最終用戶、病患類型、分銷管道和地區分類－2026-2033年產業預測

2024 年全球用於治療心臟衰竭的醫療設備市場價值為 187.4 億美元，預計到 2025 年將成長至 203.5 億美元，到 2033 年將成長至 393.8 億美元，在預測期（2026-2033 年）內複合年成長率為 8.6%。

由於人口老化以及高血壓、糖尿病和肥胖等文明病導致的心臟衰竭盛行率不斷上升，全球心臟衰竭治療設備市場正經歷強勁成長。臨床醫生和醫療系統對更先進的治療方案的需求日益成長，推動了對植入式心臟設備和遠端監測系統的需求。技術進步，特別是人工智慧驅動的診斷和無線連接的改進，正在改善患者預後並加速醫療機構的採用。此外，人們對早期診斷和長期管理的認知不斷提高，已開發市場有利的報銷政策以及新興經濟體醫療基礎設施的建設，都為這一趨勢提供了支持。越來越多的臨床證據支持心臟再同步治療和心室輔助裝置（VAD）等治療方法，進一步增強了醫生的信心，並為更廣泛的應用以及向微創、數據驅動的患者照護解決方案轉變鋪平了道路。

全球用於治療心臟衰竭的醫療設備市場按器材類型、應用、最終用戶、患者類型、分銷管道和地區進行細分。依器械類型分類，市場分為心室輔助裝置 (VAD)、心臟再同步治療 (CRT) 裝置、植入式心臟整流去顫器(ICD) 和遠端監測裝置。按應用分類，市場分為急性心臟衰竭和慢性心臟衰竭。依最終用戶分類，市場分為醫院、心臟中心和門診手術中心。依患者類型分類，市場分為成人和兒童。按分銷通路分類，市場分為直銷和分銷商。依地區分類，市場分為北美、歐洲、亞太、拉丁美洲以及中東和非洲。

全球心臟衰竭治療設備市場的成長要素

全球心臟衰竭治療設備市場正受到老齡人口成長的顯著影響，而老齡人口的成長與心臟衰竭盛行率的上升密切相關。這種人口結構的變化催生了對治療和監測設備的迫切需求，醫療專業人員也尋求更有效的治療方法。因此，專為老年人設計的先進植入式和穿戴式醫療設備的需求日益成長。這一趨勢正推動企業創新，開發針對老年族群的新產品，隨著全球治療中心越來越積極採用這些解決方案，市場成長也進一步加速。此外，監管機構也越來越重視針對特定年齡層的醫療設備臨床試驗，有助於加快市場上的研發和核准流程。

全球心臟衰竭醫療設備市場面臨的限制因素

先進心臟衰竭治療設備的高成本對市場構成重大挑戰。尤其是在保險報銷系統有限的新興地區，許多醫療保健計劃難以承擔這些技術部署的成本。初始購置成本和持續維護費用帶來的經濟負擔，可能迫使醫療機構選擇較傳統的治療方法，而非採用創新解決方案。因此，預算限制阻礙了設備的普及，導致儘管臨床療效顯著，但市場滲透率仍然不足。雖然製造商通常會調整定價策略以提高可及性，但保險公司可能會推遲承保決定，直到獲得足夠的長期治療結果數據，這進一步限制了患者的就醫途徑，並延緩了臨床應用。

全球心臟衰竭治療設備市場趨勢

在全球心臟衰竭治療設備市場，互聯健康平台的興起正推動遠端監測的顯著發展趨勢。這些平台透過創新的穿戴式感測器和植入式遙測系統，能夠對心臟生物標記和患者活動進行持續、非侵入性的追蹤，從而實現全天候監測。這項技術進步使臨床醫生能夠接收即時警報，及時調整用藥方案，及早發現潛在併發症，最終降低患者的再入院率，提高其生活品質。隨著醫療保健模式日益向價值導向醫療模式轉變，製造商正優先開發下一代心臟衰竭治療設備中的互通通訊協定和先進的數據分析功能，以支援全球範圍內的個人化治療策略。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球用於治療心臟衰竭的醫療設備市場規模：按器材類型分類

• 心室輔助裝置（VAD）
• 心臟再同步治療（CRT）裝置
• 植入式心臟整流去顫器（ICD）
• 遠端監控設備

全球用於治療心臟衰竭的醫療設備市場規模：按應用領域分類

• 急性心臟衰竭
• 慢性心臟衰竭

用於治療心臟衰竭的醫療設備的全球市場規模：按最終用戶分類。

• 醫院
• 心臟中心
• 門診手術中心

全球用於治療心臟衰竭的醫療設備市場規模：按患者類型分類

• 成人
• 兒童

全球用於治療心臟衰竭的醫療設備市場規模：按分銷管道分類

• 直銷
• 銷售代理

全球用於治療心臟衰竭的醫療設備市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Abbott Laboratories
• Medtronic plc
• Edwards Lifesciences Corporation
• Boston Scientific Corporation
• Johnson & Johnson
• Abiomed, Inc.
• LivaNova PLC
• Getinge AB
• Terumo Corporation
• Berlin Heart GmbH
• Jarvik Heart, Inc.
• CorWave SA
• Evaheart, Inc.
• SynCardia Systems, LLC
• Bivacor, Inc.
• Teleflex Incorporated
• Koninklijke Philips NV
• GE HealthCare Technologies Inc.
• Siemens Healthineers AG
• Nipro Corporation

結論與建議

Global Heart Failure Device Market size was valued at USD 18.74 Billion in 2024 and is poised to grow from USD 20.35 Billion in 2025 to USD 39.38 Billion by 2033, growing at a CAGR of 8.6% during the forecast period (2026-2033).

The global heart failure device market is experiencing robust growth due to rising heart failure incidences linked to aging populations and lifestyle diseases such as hypertension, diabetes, and obesity. Clinicians and health systems are increasingly seeking advanced options, driving demand for implantable cardiac devices and remote monitoring systems. Technological advancements, particularly AI-enabled diagnostics and improved wireless connectivity, are enhancing patient outcomes and encouraging hospital adoption. Moreover, heightened awareness of early diagnosis and long-term management, coupled with favorable reimbursement policies in developed markets and improved healthcare infrastructure in emerging economies, facilitate this trend. Increasing clinical evidence supporting therapies like cardiac resynchronization and ventricular assist devices further bolsters physician confidence, paving the way for broader utilization and a shift toward less invasive, data-driven solutions in patient care.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Heart Failure Device market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Heart Failure Device Market Segments Analysis

The global heart failure device market is segmented by device type, application, end user, patient type, distribution channel and region. Based on device type, the market is segmented into Ventricular Assist Devices (VADs), Cardiac Resynchronization Therapy (CRT) Devices, Implantable Cardioverter Defibrillators (ICDs) and Remote Monitoring Devices. Based on application, the market is segmented into Acute Heart Failure and Chronic Heart Failure. Based on end user, the market is segmented into Hospitals, Cardiac Centers and Ambulatory Surgical Centers. Based on patient type, the market is segmented into Adult and Pediatric. Based on distribution channel, the market is segmented into Direct Sales and Distributors. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Heart Failure Device Market

The Global Heart Failure Device market is significantly influenced by the increasing elderly population, which correlates with a rising prevalence of heart failure. This demographic shift creates an urgent demand for both therapeutic and monitoring devices, prompting healthcare providers to seek effective interventions for their patients. Consequently, there is a growing preference for advanced implantable and wearable devices tailored specifically for older adults. This trend encourages companies to innovate new products designed for this age group, further driving market growth as treatment centers worldwide become more receptive to these solutions. Additionally, regulatory bodies are placing greater emphasis on age-specific device trials, contributing to the accelerated development and approval processes in the market.

Restraints in the Global Heart Failure Device Market

The high cost associated with advanced heart failure devices presents a significant challenge for the market. Many healthcare systems, particularly in emerging regions with restricted reimbursement frameworks, find it difficult to afford these technologies. The financial burden stemming from both initial purchase and ongoing maintenance can compel providers to opt for older, more traditional treatment options rather than embracing innovative solutions. Consequently, limited budgets hinder widespread adoption, resulting in inadequate market penetration despite evident clinical advantages. Manufacturers often reevaluate their pricing strategies to enhance accessibility, while insurers may delay coverage decisions until sufficient long-term outcome data is available, further restricting patient access and slowing real-world integration.

Market Trends of the Global Heart Failure Device Market

The Global Heart Failure Device market is witnessing a significant trend towards remote monitoring integration, propelled by the rise of connected health platforms. These platforms facilitate continuous, non-invasive tracking of cardiac biomarkers and patient activities through innovative wearable sensors and implantable telemetry systems, essentially providing round-the-clock surveillance. This technological advancement empowers clinicians with real-time alerts, enabling timely medication adjustments and early detection of potential complications, ultimately leading to reduced hospital readmissions and enhanced patient quality of life. As the healthcare landscape increasingly aligns with value-based care models, manufacturers are prioritizing the development of interoperable communication protocols and advanced data analytics features in next-generation heart failure devices, supporting tailored therapeutic strategies on a global scale.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Heart Failure Device Market Size by Device Type & CAGR (2026-2033)

• Market Overview
• Ventricular Assist Devices (VADs)
• Cardiac Resynchronization Therapy (CRT) Devices
• Implantable Cardioverter Defibrillators (ICDs)
• Remote Monitoring Devices

Global Heart Failure Device Market Size by Application & CAGR (2026-2033)

• Market Overview
• Acute Heart Failure
• Chronic Heart Failure

Global Heart Failure Device Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Cardiac Centers
• Ambulatory Surgical Centers

Global Heart Failure Device Market Size by Patient Type & CAGR (2026-2033)

• Market Overview
• Adult
• Pediatric

Global Heart Failure Device Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Direct Sales
• Distributors

Global Heart Failure Device Market Size & CAGR (2026-2033)

• North America (Device Type, Application, End User, Patient Type, Distribution Channel)
  • US
  • Canada
• Europe (Device Type, Application, End User, Patient Type, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Device Type, Application, End User, Patient Type, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Device Type, Application, End User, Patient Type, Distribution Channel)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Device Type, Application, End User, Patient Type, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Abbott Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medtronic plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Edwards Lifesciences Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boston Scientific Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abiomed, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• LivaNova PLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Getinge AB
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Terumo Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Berlin Heart GmbH
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Jarvik Heart, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CorWave SA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Evaheart, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• SynCardia Systems, LLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bivacor, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teleflex Incorporated
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Koninklijke Philips N.V.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GE HealthCare Technologies Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthineers AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nipro Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations